KalVista Pharmaceuticals saw a significant surge in its stock price, closing at $26.67, marking a remarkable 38.62% increase. This positive movement followed the announcement that the Italian pharmaceutical company Chiesi Group has entered into an agreement to acquire KalVista for $27 per share in cash. The potential deal has captured investor attention, particularly concerning the associated risks of deal closure and the need for regulatory approvals.
Trading activity for KalVista was notably high, with approximately 71 million shares exchanged, a staggering 3,323% increase compared to its three-month average of 2 million shares. KalVista, which has been public since 2015, has faced challenges in its stock performance, falling 66% since its initial public offering.
In broader market news, the S&P 500 experienced a slight dip of 0.02%, closing at 7,138, while the Nasdaq Composite saw a marginal rise of 0.04%, ending the day at 24,673. The biotechnology sector presented a mixed bag; for instance, Prothena, a competitor in the space, saw its shares fall 5.56%, closing at $10.87 as investors evaluated the risks surrounding drug pipelines and recent deal activities.
For investors, KalVista’s stock gain appears to reflect a strong belief that the acquisition deal with Chiesi will proceed. The acquisition is particularly intriguing given that KalVista has been one of the most shorted stocks on the market, with short interest levels reaching 40%. This comes at a time when KalVista’s flagship product, EKTERLY, an oral treatment for hereditary angioedema—a rare condition affecting approximately 1 in 50,000 people—was only recently approved in July 2025 and has reported three quarters of revenue since its launch.
Chiesi’s broader international presence may bolster the reach of EKTERLY and enhance its accessibility to those affected by this rare disease, thus potentially benefiting both companies if the acquisition goes through.
